Telmisartan and Insulin Resistance in HIV (TAILoR): Protocol for a doseranging phase II randomised openlabelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy

BMJ Open

Volumn 5, Issue 10, 2015, Pages

  Pushpakom, Sudeep P ^a   Taylor, Claire ^a   Kolamunnage Dona, Ruwanthi ^a   Spowart, Catherine ^a   Vora, Jiten ^b   García Fiñana, Marta ^a   Kemp, Graham J ^a   Whitehead, John ^c   Jaki, Thomas ^c   Khoo, Saye ^a   Williamson, Paula ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 6; KIM 1 PROTEIN; LIPID; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; RBP PROTEIN; RESISTIN; TELMISARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ARTICLE; BLOOD LEVEL; BODY FAT DISTRIBUTION; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; URINE LEVEL; ADOLESCENT; ADULT; AGED; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; HIV INFECTIONS; METHODOLOGY; MIDDLE AGED; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZIMIDAZOLES; BENZOATES; CLINICAL PROTOCOLS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; RESEARCH DESIGN; YOUNG ADULT;

EID: 84945584299     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009566     Document Type: Article

References (55)

1. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13.
2. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-35.
3. Potthoff A, Brockmeyer NH, Gelbrich G, et al. Lipodystrophy - a sign for metabolic syndrome in patients of the HIV-HEART study. J Dtsch Dermatol Ges 2010;8:92-8.
4. Paula AA, Falcão MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther 2013;10:32.
5. Worm SW, Friis-Møller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010;24:427-35.
6. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165:1179-84.
7. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224-9.
8. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
9. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24.
10. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010;24:243-53.
11. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009;50:499-505.
12. Djedaini M, Peraldi P, Drici MD, et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 2009;386:96-100.
13. Lee GA, Rao M, Mulligan K, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS 2007;21:2183-90.
14. Palacios R, Merchante N, Macias J, et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006;11:529-35.
15. Bernal E, Masiá M, Padilla S, et al. Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir. Med Clin 2007;129:252-4.
16. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007;46:283-90.
17. Jones SP, Janneh O, Back DJ, et al. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005;10:207-13.
18. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004;9:911-20.
19. Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 2004;38:448-57.
20. McGoldrick C, Leen CL. The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Med 2007;8:325-34.
21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
22. Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010;10:183.
23. Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metab Clin Exp 2006;55:1159-64.
24. Younis F, Stern N, Limor R, et al. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metab Clin Exp 2010;59:1200-9.
25. Foryst-Ludwig A, Hartge M, Clemenz M, et al. PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovas Diabetol 2010;9:64.
26. Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, et al. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci 2010;119:239-50.
27. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007;32:261-8.
28. Makita S, Abiko A, Naganuma Y, et al. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metab Clin Exp 2008;57:1473-8.
29. Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009;15:942-54.
30. Rizos CV, Milionis HJ, Kostapanos MS, et al. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther 2010;32:492-505.
31. Chujo D, Yagi K, Asano A, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 2007;30:1205-10.
32. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007;25:841-8.
33. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
34. Boccara F, Auclair M, Cohen A, et al. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther 2010;15:363-75.
35. Singh B, Saxena A. Surrogate markers of insulin resistance: a review. World J Diabetes 2010;1:36-47.
36. Takagi H, Umemoto T. Telmisartan improves insulin sensitivity: a meta-analysis of randomized head-to-head trials. Int J Cardiol 2012;156:92-6.
37. Ucciferri C, Falasca K, Mancino P, et al. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Eur Rev Med Pharmacol Sci 2012;16:491-8.
38. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005;54:122-7.
39. Rico-Sanz J, Thomas EL, Jenkinson G, et al. Diversity in levels of intracellular total creatine and triglycerides in human skeletal muscles observed by (1)H-MRS. J Appl Physiol 1999;87:2068-72.
40. Dunnett C. Selection of the best treatment in comparison to a control with an application to a medical trial. In: Santer T, Tamhane AC, eds. Design of experiments: ranking and selection. New York: Marcel Dekker, 1984:47-66.
41. Magirr D, Jaki T, Whitehead J. A generalized Dunnett test for multi-arm multistage clinical studies with treatment selection. Biometrika 2012;99:494-501.
42. Whitehead J, Jaki T. One-and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. Stat Med 2009;28:828-47.
43. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000;1:465-80.
44. Williamson PR, Kolamunnage-Dona R, Philipson P, et al. Joint modelling of longitudinal and competing risks data. Stat Med 2008;27:6426-38.
45. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res 2010;19:237-70.
46. NIH. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 December, 2004; Clarification August 2009. 2004.
47. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-67.
48. Stangier J, Su CA, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000;40(12 Pt 1):1355-64.
49. Depart of Health MRC, Medicines and Healthcare Products Regulatory Agency Clinical Trials Working Group. 2011. Risk-adaptedápproaches-to-the-managementóf-clinical-trialsóf-investigational-medicinal-products.pdf
50. Araujo S, Bañón S, Machuca I, et al. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs. Eur J Endocrinol 2014;171:545-54.
51. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013;382:1525-33.
52. Vecchiet J, Ucciferri C, Falasca K, et al. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther 2011;16:639-45.
53. Lake JE, Tseng CH, Currier JS. A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. PLoS ONE 2013;8:e58135.
54. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8.
55. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol 2014;10:293-302.